Topical Ruxolitinib Evaluation in Immune-related Vitiligo-like Depigmentation
NCT07725432
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
34
Enrollment
OTHER
Sponsor class
Conditions
Immune-related Vitiligo-like-Depigmentation
Interventions
DRUG:
Ruxolitinib Topical Cream
Sponsor
University of Zurich